menu
    • menu

    Company profile for Prelude Therapeutics

    NEW Drugs in Dev: 9
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with experience in developing cancer medicines to create a next generation cancer drug discovery company.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Prelude TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Powder Mill Road Wilmington, DE 19803 Phone: (302) 467-1280
    Telephone
    Telephone
    (302)467-1280
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://preludetx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ELCC

    ELCC

    Not Confirmed

    envelop Contact Supplier

    ELCC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Prelude Announces Acceptance of Preclinical Abstract for PRT13722
    Prelude Announces Acceptance of Preclinical Abstract for PRT13722

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257688/0/en/Prelude-Therapeutics-Announces-Acceptance-of-Preclinical-Abstract-for-PRT13722-a-First-in-Class-Oral-KAT6A-Selective-Degrader-at-the-2026-AACR-Annual-Meeting.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Prelude Pharma Reveals 2025 Financials, 2026 Program Outlook
    Prelude Pharma Reveals 2025 Financials, 2026 Program Outlook

    10 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/10/3252633/0/en/Prelude-Therapeutics-Reports-Full-Year-2025-Financial-Results-and-Provides-Program-Outlook-for-2026.html

    GLOBENEWSWIRE
    10 Mar 2026
    Share Share
    Prelude Gets IND Clearance for Mutant-Selective JAK2 Inhibitor
    Prelude Gets IND Clearance for Mutant-Selective JAK2 Inhibitor

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3231175/0/en/Prelude-Therapeutics-Receives-FDA-Clearance-of-Investigational-New-Drug-Application-IND-for-PRT12396-a-Mutant-selective-JAK2V617F-Inhibitor.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    Prelude Therapeutics Unveils Myeloproliferative Neoplasm Data
    Prelude Therapeutics Unveils Myeloproliferative Neoplasm Data

    06 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/06/3201071/0/en/Prelude-Therapeutics-Presents-Data-at-the-2025-ASH-Annual-Meeting-from-its-Myeloproliferative-Neoplasm-MPN-Programs.html

    GLOBENEWSWIRE
    06 Dec 2025
    Share Share
    Prelude Therapeutics Unveils Q3 Financials & Corporate Update
    Prelude Therapeutics Unveils Q3 Financials & Corporate Update

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186089/0/en/Prelude-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    Prelude Loses CMO, Pauses SMARCA2 Degraders, Scores Incyte Cash
    Prelude Loses CMO, Pauses SMARCA2 Degraders, Scores Incyte Cash

    04 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/prelude-loses-cmo-pauses-smarca2-degraders-and-bags-60m-incyte

    FIERCE BIOTECH
    04 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search